Date: 2015-02-12
Type of information: Grant
Company: AC Immune (Switzerland)
Investors: The Michael J. Fox Foundation - MJFF (USA)
Amount: undisclosed
Funding type: grant
Planned used: The grant will be used to develop Positron Emission Tomography (PET) tracers for the alpha-synuclein protein, supporting the diagnosis and clinical management of Parkinson’s disease. The research project aims to develop brain imaging agents for alpha-synuclein, a key protein involved in the pathology of Parkinson’s disease. Such an alpha-synuclein-PET imaging agent will help diagnose the disease earlier and more accurately, enable tracking of pathology over time, and monitor the efficacy of therapeutics in reducing alpha-synuclein aggregates. Using its proprietary Morphomer™ chemistry technology platform, designed to interact with the basic process of protein misfolding, AC Immune has identified promising small molecule compounds with good selectivity for alpha-synuclein and promising properties as PET ligands. The grant will allow AC Immune to develop a lead compound with suitable characteristics that could rapidly enter into clinical development.
Others: * On February 12, 2015, AC Immune announced it has been awarded a research grant by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) for the development of Positron Emission Tomography (PET) tracers for the alpha-synuclein protein, supporting the diagnosis and clinical management of Parkinson’s disease. The amount of the grant was not disclosed.
Therapeutic area: Neurodegenerative diseases
